Transforming cancer from lethal to chronic. Therapy response after 2 cycles (6 sessions) of ¹⁷⁷Lu-PSMA therapy.
Transforming cancer from lethal to chronic. Therapy response after 2 cycles of ¹⁷⁷Lu-PSMA therapy
The case illustrates the scientific findings that the radioligand therapy 177Lu-PSMA is safe and effective and can be successfully applied more than once in case of recurrence, moving towards the goal of transforming cancer from lethal into a chronic disease like any other. It also grants the patients considerably better quality of life than the protracted ADT or chemotherapy.
72 y.o. patient William Daly was first diagnosed with prostate cancer (PC) in December 2021. Despite heavy pre-treatment with several cycles of immunotherapy, cryoablation and leukin therapy, the disease continued to progress extending to lymph nodes. Mr. Daly refused constant antihormonal therapy and chemotherapy due to side effects and opted for 177Lu-PSMA targeted radioligand therapy. The patient has undergone 2 cycles 3 infusions each of the therapy. After the first one, PC went into remission for 1,5 years.
BEFORE 1st cycle | AFTER 1st cycle |
PSMA PET/CT October 2021
PSA 45 ng/ml. High PSMA-expressing lymph node metastases. |
PSMA PET/CT April 2022
PSA 0,18 ng/ml. After 3x 177Lu-PSMA therapy sessions from December 2021 to February 2022, significant remission of the retroperitoneal and locoregional lymph node metastases. PSA decline was documented until October 2022 with a Nadir of 2,39ng/ml. |
BEFORE 2nd cycle | AFTER 2nd cycle |
PSMA PET/CT September 2023
PSA 23,3ng/ml Progressive retroperitoneal lymph node disease with two new bone lesions as well as progression in the prostate. 3-session cycle of 177Lu-PSMA radioligand therapy is repeated 1,5 years after the first one. A short-term complimentary ADT with Relugolix was initiated along with the RLT to increase PSMA expression. |
PSMA PET/CT April 2024
PSA 0,1 ng/ml After 3x 177Lu-PSMA radioligand therapy sessions from December 2023 to February 2024 no activity in the metastases was detected in September 2023. The only side effect reported was short-term mild nausea and mild fatigue after the treatment. Meanwhile the patient stopped all medication and reports general well-being and regained strength. |
Read Mr. Daly's story in his own words:
"My story began in December 2014 when I was diagnosed with prostate cancer (PC). It was identified as “intermediate risk” with a Gleason score of 7 (3+4) in 3 of the 12 biopsy samples taken. At this point it had not spread, but after an MRI, it showed an “extracapsular extension”. I chose not to have surgery and decided to do watchful waiting. I also wanted to stay away from hormone therapy.
After another MRI, it showed that the PC was very near the seminal vesicles and I engaged a doctor in Fort Lauderdale, Florida to help me with treatment. He performed a 3D mapping biopsy that showed Gleason 8 in the prostate. Then he treated the PC with focal cryoablation, and my PSA went from 9 to 0.6. This was done in October 2017.
The PSA stayed there for about 2 years before it began to gradually move up. As it happens, I was treated for a kidney stone in July of 2020 and a swollen lymph node was noted in my pelvis area. After another MRI, my doctor in Florida suggested that we go through immune therapy. His immune therapy was very successful in some of his patients – but I did not respond to it. It was at that time that we pursued the 177Lu-PSMA treatment with Dr. Hartenbach. First, I had a PSMA scan done in Houston, Texas to see if the treatment could be done at all. After approval, I made arrangements to go through the therapy with Dr. Hartenbach. My PSA was about 48 at that time. That was in the fall of 2021.
After 1 cycle (3 infusions) of the therapy, my PSA was 2.39. The follow-up PSMA scan showed a remarkable improvement. There were only a couple of places where the cancer was still in the process of dying. We were very pleased at the response. This was in the spring of 2022 and the therapy had given me 2 years of remission. After closely monitoring the PC with scheduled labs, the PSA began to move up again. When it reached 23, we felt more treatment would be beneficial.
So, in December of 2023 I started another cycle of the 177Lu-PSMA therapy. We also added a drug called Orgovyx to the therapy. The PSMA scan was done in April after the treatment was completed in February 2024. I guess I can say that I experienced minimal side effects from the treatment (some nausea for a couple of days and some “dry mouth”). So, all in all, I was treated with 2 cycles (6 actual infusions) by Dr. Hartenbach.
This time, the results of the treatment and scan were remarkable. The PSMA scan was clear and the report said I had a “complete response” to the therapy – my PSA is now 0.1. This couldn’t have been a better result and I was so grateful and blessed to have been working with Dr. Hartenbach and his staff. I am praying for a long - term remission.
Thanks again for Dr. Hartenbach and all his staff."